202 related articles for article (PubMed ID: 22444689)
21. Pathobiology of lymphoid and myeloid blast crisis and management issues.
Ilaria RL
Hematology Am Soc Hematol Educ Program; 2005; ():188-94. PubMed ID: 16304379
[TBL] [Abstract][Full Text] [Related]
22. Use of imatinib mesylate for favorable control of hypercalcemia mediated by parathyroid hormone-related protein in a patient with chronic myelogenous leukemia at blast phase.
Miyoshi N; Tanaka H; Ito T; Katayama Y; Niimi H; Hyodo H; Kimura A
Int J Hematol; 2005 Nov; 82(4):333-7. PubMed ID: 16298826
[TBL] [Abstract][Full Text] [Related]
23. Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia.
Liu NS; O'Brien S
Leuk Lymphoma; 2002 Dec; 43(12):2413-5. PubMed ID: 12613534
[TBL] [Abstract][Full Text] [Related]
24. Concurrent megakaryocytic and erythroid chronic myelogenous leukemia blast crisis.
Westfall DE; Zhang L; Song S; Lee S
Arch Pathol Lab Med; 2008 Jun; 132(6):1021-5. PubMed ID: 18517263
[TBL] [Abstract][Full Text] [Related]
25. Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia.
Kong JH; Yoo SH; Lee KE; Nam SH; Kwon JM; Lee SM; Chang HJ; Choi MY; Cho MS; Mun YC; Nam E; Lee SN; Seong CM
Acta Haematol; 2007; 118(4):205-8. PubMed ID: 18030002
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
27. A 51-year-old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment.
Janssen JJ; Berendse HW; Schuurhuis GJ; Merle PA; Ossenkoppele GJ
Am J Hematol; 2009 Oct; 84(10):679-82. PubMed ID: 19658186
[No Abstract] [Full Text] [Related]
28. Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy.
Druker BJ
Eur J Cancer; 2002 Sep; 38 Suppl 5():S70-6. PubMed ID: 12528776
[TBL] [Abstract][Full Text] [Related]
29. Extramedullary blast crisis occurring in a Philadelphia-positive chronic myeloid leukemia patient with major cytogenetic response to imatinib.
Breccia M; Nanni M; Mancini F; Russo E; Mecarocci S; Alimena G
Haematologica; 2004 Apr; 89(4):ECR11. PubMed ID: 15075103
[No Abstract] [Full Text] [Related]
30. Fluorescence in situ hybridization for the BCR-ABL fusion gene in a patient with imatinib mesylate-resistant chronic myelogenous leukaemia in extramedullary blast crisis.
Mori T; Yamazaki R; Ikeda Y; Okamoto S
Br J Haematol; 2003 May; 121(4):533. PubMed ID: 12752093
[No Abstract] [Full Text] [Related]
31. Case of chronic-phase chronic myelogenous leukemia with an abdominal hematopoietic tumor of leukemic clone origin.
Sakakura M; Ohishi K; Nomura K; Katayama N; Nishii K; Masuya M; Nakase K; Shiku H
Am J Hematol; 2004 Oct; 77(2):167-70. PubMed ID: 15389905
[TBL] [Abstract][Full Text] [Related]
32. Complete remission from chronic myelogenous leukemia--blastic crisis caused by reduced intensity stem cell transplantation following partial remission due to imatinib.
Myojo T; Hino N
Intern Med; 2004 Feb; 43(2):126-30. PubMed ID: 15005255
[TBL] [Abstract][Full Text] [Related]
33. Unusual extramedullary relapses under imatinib mesylate treatment in chronic myeloid leukemia.
Beyazit Y; Aksu S; Kekilli M; Haznedaroglu IC; Kilickap S; Goker H
Am J Hematol; 2005 May; 79(1):79-80. PubMed ID: 15849758
[No Abstract] [Full Text] [Related]
34. Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
Thota NK; Gundeti S; Linga VG; Coca P; Tara RP;
Indian J Cancer; 2014; 51(1):5-9. PubMed ID: 24947087
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of chronic myelogenous leukemia by using imatinib].
Jinnai I
Nihon Naika Gakkai Zasshi; 2005 Sep; 94(9):1819-24. PubMed ID: 16223141
[No Abstract] [Full Text] [Related]
36. Early blastic transformation with CNS infiltration in a patient with chronic myeloid leukaemia treated with imatinib.
Pavlu J; Czepulkowski B; Kaczmarski R; Jan-Mohamed R
Lancet Oncol; 2005 Feb; 6(2):128. PubMed ID: 15683824
[No Abstract] [Full Text] [Related]
37. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
Chung HJ; Chi HS; Cho YU; Park CJ; Seo EJ; Kim KH; Lee JH
Ann Clin Lab Sci; 2008; 38(3):283-6. PubMed ID: 18715859
[TBL] [Abstract][Full Text] [Related]
38. Megakaryocytic blast crisis at presentation in a pediatric patient with chronic myeloid leukemia.
Al-Shehri A; Al-Seraihy A; Owaidah TM; Belgaumi AF
Hematol Oncol Stem Cell Ther; 2010; 3(1):42-6. PubMed ID: 20231813
[TBL] [Abstract][Full Text] [Related]
39. Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib.
Kim HJ; Jung CW; Kim K; Ahn JS; Kim WS; Park K; Ko YH; Kang WK; Park K
J Clin Oncol; 2006 Aug; 24(24):4028-9. PubMed ID: 16921058
[No Abstract] [Full Text] [Related]
40. An unusual case of extramedullary blast crisis in chronic myelocytic leukaemia.
Feng CS
Am J Hematol; 1988 Oct; 29(2):117-9. PubMed ID: 3189299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]